Masashi Takano

Summary

Affiliation: National Defense Medical College
Country: Japan

Publications

  1. Aoyama T, Takano M, Miyamoto M, Yoshikawa T, Kato K, Sakamoto T, et al. Pretreatment Neutrophil-to-Lymphocyte Ratio Was a Predictor of Lymph Node Metastasis in Endometrial Cancer Patients. Oncology. 2019;:1-9 pubmed publisher
    ..039). A higher pretreatment NLR was identified as a predictor of LN metastasis in endometrial cancers. Although further study is needed to confirm the results, NLR could be a candidate clinical marker for detection of LN metastasis. ..
  2. Takano M, Sugiyama T, Yaegashi N, Sagae S, Kuzuya K, Udagawa Y, et al. Less impact of adjuvant chemotherapy for stage I clear cell carcinoma of the ovary: a retrospective Japan Clear Cell Carcinoma Study. Int J Gynecol Cancer. 2010;20:1506-10 pubmed publisher
    ..Further strategy, such as a molecular targeting agent, is needed to improve survival of CCC, especially in cases with positive peritoneal washing. ..
  3. request reprint
    Takano M, Sugiyama T, Yaegashi N, Suzuki M, Tsuda H, Sagae S, et al. Progression-free survival and overall survival of patients with clear cell carcinoma of the ovary treated with paclitaxel-carboplatin or irinotecan-cisplatin: retrospective analysis. Int J Clin Oncol. 2007;12:256-60 pubmed
    ..Although there was no significant survival benefit in the present retrospective analysis, we recommend that the CPT-P regimen be evaluated in a larger, prospective, clinical trial. ..
  4. request reprint
    Takano M, Yoshikawa T, Yoshokawa T, Kato M, Aida S, Goto T, et al. Primary clear cell carcinoma of the peritoneum: report of two cases and a review of the literature. Eur J Gynaecol Oncol. 2009;30:575-8 pubmed
    ..The cases and a review of the literature suggested that residual tumor volume size determines the survival of these patients, and that the tumors show resistance to conventional platinum-based chemotherapy. ..
  5. Takano M, Sugiyama T, Yaegashi N, Suzuki M, Tsuda H, Sagae S, et al. The impact of complete surgical staging upon survival in early-stage ovarian clear cell carcinoma: a multi-institutional retrospective study. Int J Gynecol Cancer. 2009;19:1353-7 pubmed publisher
    ..More effective treatment modality was warranted, especially for CCC cases positive for malignant peritoneal cytology. ..
  6. Kato M, Takano M, Miyamoto M, Sasaki N, Goto T, Tsuda H, et al. DNA mismatch repair-related protein loss as a prognostic factor in endometrial cancers. J Gynecol Oncol. 2015;26:40-5 pubmed publisher
    ..MMR-related proteins expression was identified as an independent prognostic factor for OS, suggesting that MMR was a key biomarker for further investigations of endometrial cancers. ..
  7. Miyamoto M, Takano M, Aoyama T, Soyama H, Yoshikawa T, Tsuda H, et al. Seromucinous component in endometrioid endometrial carcinoma as a histological predictor of prognosis. J Gynecol Oncol. 2018;29:e20 pubmed publisher
    ..049). Seromucinous component was identified in approximately 10% of endometrioid carcinoma, and could be a histological predictor for prognosis. ..
  8. Miyamoto M, Takano M, Aoyama T, Soyama H, Yoshikawa T, Tsuda H, et al. Inhibition of autophagy protein LC3A as a therapeutic target in ovarian clear cell carcinomas. J Gynecol Oncol. 2017;28:e33 pubmed publisher
    ..Although further studies are needed to confirm the results, inhibition of autophagy by HCQ was associated with platinum sensitivity. Autophagy protein LC3A could be a promising target for treatment for CCC. ..
  9. Takano M, Kato M, Yoshikawa T, Sasaki N, Hirata J, Furuya K, et al. Clinical significance of UDP-glucuronosyltransferase 1A1*6 for toxicities of combination chemotherapy with irinotecan and cisplatin in gynecologic cancers: a prospective multi-institutional study. Oncology. 2009;76:315-21 pubmed publisher
    ..In patients with *28 or *28*6, side effects were similar to those in patients with *6. In addition to UGT1A1*28, UGT1A1*6 might also be a key candidate to determine the dose of combination chemotherapy with irinotecan and cisplatin. ..